Terms: = Kidney tumors AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874 AND Treatment
4 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Occurrence of non-central nervous system cancers during postoperative follow-up of patients who underwent surgery for a WHO grade II glioma: implications for therapeutic management.
Duffau H
J Neurooncol; 2023 Mar; 162(1):237-244. PubMed ID: 36913047
[TBL] [Abstract] [Full Text] [Related]
3. Wild-type idh1 inhibits the tumor growth through degrading HIF-α in renal cell carcinoma.
Chen S; Wang Y; Xiong Y; Peng T; Lu M; Zhang L; Guo Z
Int J Biol Sci; 2021; 17(5):1250-1262. PubMed ID: 33867843
[TBL] [Abstract] [Full Text] [Related]
4. Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (midh1) Inhibitors.
Lin J; Lu W; Caravella JA; Campbell AM; Diebold RB; Ericsson A; Fritzen E; Gustafson GR; Lancia DR; Shelekhin T; Wang Z; Castro J; Clarke A; Gotur D; Josephine HR; Katz M; Diep H; Kershaw M; Yao L; Kauffman G; Hubbs SE; Luke GP; Toms AV; Wang L; Bair KW; Barr KJ; Dinsmore C; Walker D; Ashwell S
J Med Chem; 2019 Jul; 62(14):6575-6596. PubMed ID: 31199148
[TBL] [Abstract] [Full Text] [Related]
